leadf
logo-loader
viewThird Pole Therapeutics

Third Pole Therapeutics anticipates FDA clearance end of 2021 to treat newborn respiratory failure

Third Pole Therapeutics CEO Bill Athenson sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The company, based in Waltham, Massachusetts, is developing transformative cardio-pulmonary therapies such as its FDA-approved pulmonary vasodilator to treat hypoxic respiratory failure in newborns.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Delta 9 Cannabis hit top 10 of Globe and Mail's Top Growth companies survey

Delta 9 Cannabis CEO John Arbuthnot joined Steve Darling from Proactive to share news the company finished 7th in the Globe and Mail’s 3rd Annual Top Company growth survey with 448 entrants based on 3-year growth. Delta 9 saw an increase of revenue over 3 years of 5,413 percent. Arbuthnot...

1 hour, 56 minutes ago

2 min read